Core Insights - Vivos Therapeutics has published peer-reviewed data confirming the safety and efficacy of its Vivos DNA appliance in treating pediatric obstructive sleep apnea (OSA) [1][2][4] - The study highlights a significant milestone in addressing pediatric OSA, a condition affecting up to 20.4% of U.S. children, with many remaining undiagnosed [3][10] Group 1: Clinical Trial Results - The multicenter clinical trial results published in the European Journal of Pediatrics show that 77% of participants experienced at least a 50% reduction in OSA severity [7] - Among children with severe OSA, 93% achieved a 50% reduction in severity, and 17% of patients experienced complete resolution of their OSA [7] - The average airway volume increased by 67.8%, and Pediatric Sleep Questionnaire symptom scores decreased by 31%, indicating statistically significant improvement [7] Group 2: Treatment Alternatives - The Vivos DNA appliance is positioned as a non-surgical alternative to the current standard of care, which is adenotonsillectomy (AT) surgery, effective in only 20-40% of pediatric cases [3][4] - Vivos also offers Vivos Guides, which support proper craniofacial growth and have shown to alleviate symptoms associated with underdeveloped jaw growth, including ADHD behaviors and bedwetting [6][15] - Clinical data indicates that Vivos Guides can virtually eliminate bedwetting in children, with 50% seeing results within two weeks and 97.4% resolving within 60 days [6] Group 3: Industry Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [10] - Vivos Therapeutics aims to address the complex needs of OSA patients through innovative technology and collaborations with healthcare providers [11] - The company’s Complete Airway Repositioning and Expansion (C.A.R.E.) devices are the only FDA-cleared technology for treating severe OSA in adults and moderate to severe OSA in children [9]

As filed with the U.S. Securities and Exchange Commission on April 8, 2024 Registration No. 333-[____] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (IRS Employer Identification No.) 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 (844) 672-4357 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) R. Kirk Huntsman Chairman of the Board and Chief Executive Officer Vivos Therapeutics, Inc. 7921 Southp ...

As filed with the U.S. Securities and Exchange Commission on November 30, 2023 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) Delaware 8011 81-3224056 (Primary Standard Industrial Classification Code Number) Registration No. 333-275726 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (IRS Employer Identification ...